Reducing Attrition through Early Assessment of Drug Safety

13 March 2014, London, United Kingdom

Introduction

Drug toxicity remains one of the main causes of compound attrition in the drug development process. Compounds displaying organ, mechanism-based or off-target toxicity are just some of the safety issues that have contributed to drug development failures, and the need for robust early drug safety screening in an integrative manner is clear.This meeting will bring together a range of international experts from both industry and academia to present the new technologies and their applications in early drug safety assessment.